EUVIMEDEUVIMED entdecken
Crossref

Taraxerol targets the HIF1A-NEK6 axis to block TDE-mediated M2 macrophage polarization and inhibits NSCLC progression

Qiang Yang, Hongli Li, Baojun Guo, Ranran Gao

Pathology - Research and Practice · 2026-10 · 286 · 156603

DOI: 10.1016/j.prp.2026.156603 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026-10. Verfasst von Qiang Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of TCM, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China. Electronic address:…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Hypoxia-Inducible Factor 1, alpha Subunit, Lung Neoplasms, Oleanolic Acid. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Non-small cell lung cancer (NSCLC) progression is tightly linked to tumor microenvironment (TME) remodeling. Taraxerol, a natural compound, has shown potential antitumor activity, but its molecular mechanisms in regulating NSCLC, particularly in TME-related progression, remain poorly characterized. METHODS Single-cell RNA sequencing (scRNA-seq) was conducted to characterize cellular heterogeneity. Network pharmacology integrated differential gene analysis and taraxerol target prediction to identify key regulatory nodes. Molecular interactions were verified via molecular docking and molecular dynamics (MD) simulations. CCK-8, EdU, flow cytometry, and Transwell were employed to assess cell proliferation, apoptosis, migration, and invasion. Xenograft models were established to elucidate taraxerol's function in vivo. Subsequently, tumor-derived exosomes (TDEs) were isolated and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot. Macrophage characteristics were validated via qRT-PCR. The interaction between hypoxia-inducible factor 1 alpha subunit (HIF1A) and NIMA-related kinase 6 (NEK6) was investigated via chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. RESULTS scRNA-seq revealed NSCLC-specific cellular remodeling, with distinct heterogeneity in macrophage subsets and altered proportions of tumor epithelial cells. HIF1A was a core target of taraxerol, confirmed by molecular docking (binding affinity -8.5 kcal/mol) and MD simulations showing stable interactions. Taraxerol inhibited HIF1A expression in A549/H1299 cells, suppressing proliferation, migration, invasion, and in vivo NSCLC tumorigenesis while promoting apoptosis. Taraxerol-treated TDEs reduced M2 polarization and migration of macrophages, while HIF1A overexpression restored these effects. Furthermore, HIF1A transcriptionally activated NEK6 by directly binding to its promoter, whereas taraxerol blocked the HIF1A-NEK6 axis-mediated promotion of macrophage M2 polarization and migration. CONCLUSION Taraxerol exerted antitumor effects in NSCLC by targeting HIF1A, thereby regulating TDE-mediated macrophage M2 polarization and tumor progression via the HIF1A-NEK6 axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungHypoxia-Inducible Factor 1, alpha SubunitLung NeoplasmsOleanolic AcidMacrophagesHumansAnimalsTumor MicroenvironmentExosomesMiceDisease ProgressionCell ProliferationSignal TransductionCell Line, TumorProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

Hypoxia-inducible factor 1 alpha subunitNIMA-related kinase 6Non-small cell lung cancerTaraxerolTumor immune microenvironmentTumor-derived exosomes

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitHIF1A protein, humanOleanolic AcidProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of TCM, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China. Electronic address: yq18103819199@163.com.
  • Department of Endocrinology, Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing 100032, China.
  • Department of TCM, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.

Zitieren

APA

Yang, Q., Li, H., Guo, B., & Gao, R. (2026). Taraxerol targets the HIF1A-NEK6 axis to block TDE-mediated M2 macrophage polarization and inhibits NSCLC progression. Pathology - Research and Practice, 286, 156603. https://doi.org/10.1016/j.prp.2026.156603

Vancouver

Yang Q, Li H, Guo B, Gao R. Taraxerol targets the HIF1A-NEK6 axis to block TDE-mediated M2 macrophage polarization and inhibits NSCLC progression. Pathology - Research and Practice. 2026;286:156603. doi:10.1016/j.prp.2026.156603

BibTeX
@article{Yang2026,
  author = {Yang, Qiang and Li, Hongli and Guo, Baojun and Gao, Ranran},
  title = {Taraxerol targets the HIF1A-NEK6 axis to block TDE-mediated M2 macrophage polarization and inhibits NSCLC progression},
  journal = {Pathology - Research and Practice},
  year = {2026},
  volume = {286},
  pages = {156603},
  doi = {10.1016/j.prp.2026.156603}
}
Kostenlos starten →